TIMABAK EYEDROPS 0.25%

Country: Singapore

Language: English

Source: HSA (Health Sciences Authority)

Active ingredient:

TIMOLOL MALEATE

Available from:

DCH AURIGA SINGAPORE

ATC code:

S01ED01

Dosage:

0.25 g/100 ml

Pharmaceutical form:

SOLUTION

Composition:

TIMOLOL MALEATE 0.25 g/100 ml

Administration route:

OPHTHALMIC

Prescription type:

Prescription Only

Manufactured by:

EXCELVISION

Authorization status:

ACTIVE

Authorization date:

1999-07-30

Patient Information leaflet

00000000
00000000
Timabak,
eye drop solution
Timolol
1. NAME OF MEDICINAL PRODUCT
TIMABAK 0.25%, eye drop solution
TIMABAK 0.50%, eye drop solution
2. QUALITATIVE AND QUANTITATIVE
COMPOSITION
Timolol
...........................................................0.250 g
In the form of timolol maleate .............0.343 g
For 100 ml of solution
Timolol
...........................................................0.500 g
In the form of timolol maleate .............0.685 g
For 100 ml of solution
See section 6.1 for the complete list of
excipients.
3. PHARMACEUTICAL FORM
Eye drop solution.
Clear colourless liquid.
4. CLINICAL PARTICULARS
4.1. Clinical indications
Intra-ocular hypertension.
Chronic wide-angle glaucoma.
4.2. Dosage and route of administration
Ophthalmic route.
Dosage
It is recommended to start the treatment by
instilling 1 drop of TIMABAK 0.25% in the
afflicted eye twice daily.
In cases of insufficient effectiveness, 1 drop
of the higher concentration TIMABAK 0.50%
should be used twice daily in the afflicted
eye.
If they deem necessary, the ophthalmologist
can combine TIMABAK with one or more
other anti-glaucoma treatments (ocular and/
or other route of administration).
However, it is not recommended to combine
two beta-blocking eye drop solutions (see
section 4.4).
The other eye drop solutions should be
administered at least 15 minutes before
TIMABAK.
In any case, it may take several weeks before
ocular pressure returns to normal with
TIMABAK eye drops. An assessment of the
treatment should also include measurement
of the intraocular eye pressure after
approximately 4 weeks of treatment.
In certain cases, a daily administration of just
1 drop of TIMABAK eye drops may prove
sufficient, in particular when the intraocular
pressure is maintained at satisfactory levels.
The systemic passage may be reduced by
nasolacrimal occlusion or by closing the
eyelids for 2 minutes. This method may help
to reduce systemic side effects and increase
local effectiveness.
Replacement of a previous treatment
When TIMABAK is used

Summary of Product characteristics

00000000
00000000
Timabak,
eye drop solution
Timolol
1. NAME OF MEDICINAL PRODUCT
TIMABAK 0.25%, eye drop solution
TIMABAK 0.50%, eye drop solution
2. QUALITATIVE AND QUANTITATIVE
COMPOSITION
Timolol ........................................................0.250
g
In the form of timolol maleate ..........0.343 g
For 100 ml of solution
Timolol ........................................................0.500
g
In the form of timolol maleate ..........0.685 g
For 100 ml of solution
See section 6.1 for the complete list of
excipients.
3. PHARMACEUTICAL FORM
Eye drop solution.
Clear colourless liquid.
4. CLINICAL PARTICULARS
4.1. Clinical indications
Intra-ocular hypertension.
Chronic wide-angle glaucoma.
4.2. Dosage and route of administration
Ophthalmic route.
Dosage
It is recommended to start the treatment by
instilling 1 drop of TIMABAK 0.25% in the
afflicted eye twice daily.
In cases of insufficient effectiveness,
1 drop of the higher concentration
TIMABAK 0.50% should be used twice
daily in the afflicted eye.
If they deem necessary, the
ophthalmologist can combine TIMABAK
with one or more other anti-glaucoma
treatments (ocular and/or other route of
administration).
However, it is not recommended to
combine two beta-blocking eye drop
solutions (see section 4.4).
The other eye drop solutions should be
administered at least 15 minutes before
TIMABAK.
In any case, it may take several weeks
before ocular pressure returns to normal
with TIMABAK eye drops. An assessment
of the treatment should also include
measurement of the intraocular eye
pressure after approximately 4 weeks of
treatment.
In certain cases, a daily administration
of just 1 drop of TIMABAK eye drops
may prove sufficient, in particular when
the intraocular pressure is maintained at
satisfactory levels.
The systemic passage may be reduced by
nasolacrimal occlusion or by closing the
eyelids for 2 minutes. This method may
help to reduce systemic side effects and
increase local effectiveness.
Replacement of a previous treatment
When TIMABAK is used to replace o